Bigul

Caplin Point eye drops get FDA nod

Caplin Steriles, subsidiary of Caplin Point Laboratories, bags FDA nod for eye drops used to treat conjunctivitis, corneal ulcer
16-04-2024
Bigul

CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Please find the attached Press Release on USFDA approval for Ofloxacin Ophthalmic Solution ANDA.
16-04-2024
Bigul

CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 is enclosed.
02-04-2024
Bigul

CAPLIN POINT LABORATORIES LTD. - 524742 - Regulation 7(3) - Compliance Certificate For The Year Ended March 31, 2024

Compliance Certificate under Regulation 7(3) is enclosed herewith.
02-04-2024
Bigul

CAPLIN POINT LABORATORIES LTD. - 524742 - Closure of Trading Window

The details regarding trading window closure for the year ending March 31, 2024 is attached herewith.
28-03-2024
Bigul

Caplin Point's subsidiary receives FDA approval for generic eye drops, shares up 2.78%

Additionally, Caplin is working on a portfolio of 40+ simple and complex Injectable and Ophthalmic products, intending to file them over the next 4 years
28-03-2024
Bigul

CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press release regarding grant of final from the USFDA for ANDA Ketorolac tromethamine Ophthalmic Solution 0.5% is attached herewith
28-03-2024
Bigul

CAPLIN POINT LABORATORIES LTD. - 524742 - Commencement Of Operations By Caplin One Labs Limited, Wos Of The Company

Press release regarding completion of state-of-art Oncology facility and commencement of operations by Caplin One Labs Limited, the WoS of the company is attached herewith
27-03-2024
Next Page
Close

Let's Open Free Demat Account